Clinical Trial Update: Treatment With SU11248 in Patients With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of SU11248 (sunitinib) in patients with neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED